Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab‐Treated Advanced Melanoma

Pembrolizumab is a potent immune‐modulating antibody active in advanced melanoma, as demonstrated in the KEYNOTE‐001, ‐002, and ‐006 studies. Longitudinal tumor size modeling was pursued to quantify exposure‐response relationships for efficacy. A mixture model was first developed based on an initial...

Descripción completa

Detalles Bibliográficos
Autores principales: Chatterjee, MS, Elassaiss‐Schaap, J, Lindauer, A, Turner, DC, Sostelly, A, Freshwater, T, Mayawala, K, Ahamadi, M, Stone, JA, de Greef, R, Kondic, AG, de Alwis, DP
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270297/
https://www.ncbi.nlm.nih.gov/pubmed/27896938
http://dx.doi.org/10.1002/psp4.12140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270297/
https://www.ncbi.nlm.nih.gov/pubmed/27896938
http://dx.doi.org/10.1002/psp4.12140

Ejemplares similares